Isabel Verduyn van Weegen - 07 Nov 2025 Form 4 Insider Report for Evommune, Inc.

Role: Director, 10%+ Owner
Signature: /s/ Gregory S. Moss, Attorney-in-Fact
Issuer symbol: EVMN on NYSE
Transactions as of: 07 Nov 2025
Net transactions value: +$25,000,000
Form type: 4
Filing time: 12 Nov 2025, 16:24:08 UTC
Previous filing: 05 Nov 2025
Next filing: 18 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Verduyn-van Weegen Felice Isabel	Director, 10%+ Owner	C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO	/s/ Gregory S. Moss, Attorney-in-Fact	12 Nov 2025	0002094941

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EVMN	Common Stock	Conversion of derivative security		+3,367,133			3,367,133	07 Nov 2025	By LSP 7 Cooperatief U.A.	F1, F2, F3, F4
transaction	EVMN	Common Stock	Purchase	$25,000,000	+1,562,500	+46%	$16.00	4,929,633	07 Nov 2025	By LSP 7 Cooperatief U.A.	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EVMN	Series A Preferred Stock	Conversion of derivative security		-15,493,466	-100%		0	07 Nov 2025	Common Stock	1,947,477		By LSP 7 Cooperatief U.A.	F1, F4
transaction	EVMN	Series B Preferred Stock	Conversion of derivative security		-5,090,000	-100%		0	07 Nov 2025	Common Stock	646,587		By LSP 7 Cooperatief U.A.	F2, F4
transaction	EVMN	Series C Preferred Stock	Conversion of derivative security		-6,585,011	-100%		0	07 Nov 2025	Common Stock	773,069		By LSP 7 Cooperatief U.A.	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date.
F2	Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.
F3	Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.
F4	These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein.